PRECLINICAL CHARACTERIZATION OF THE NOVEL, ORALLY BIOAVAILABLE HEPATITIS B VIRAL ENTRY INHIBITOR A2342

被引：0

作者：

Lindstrom, Erik ^{[1
]}

Gillberg, Per-Goran ^{[1
]}

Uzelac, Ivana ^{[1
]}

Starke, Ingemar ^{[1
]}

Bonn, Britta ^{[1
]}

Strangberg, Ellen ^{[1
]}

Mattsson, Jan ^{[1
]}

Akerblad, Peter ^{[1
]}

Pal, Runa ^{[2
]}

Gaur, Ashwani ^{[2
]}

Kangarajan, Ramesh ^{[2
]}

Singh, Shivendra ^{[2
]}

Kulkarni, Santosh ^{[2
]}

Truong, Jennifer ^{[3
]}

Rao, Anuradha ^{[3
]}

Dawson, Paul A. ^{[3
]}

机构：

[1] Albireo Pharma Inc, Boston, MA USA

[2] Syngene Int Ltd, Bangalore, Karnataka, India

[3] Emory Univ, Sch Med, Div Pediat Gastroenterol Hepatol & Nutr, Atlanta, GA 30322 USA

来源：

HEPATOLOGY | 2021年 / 74卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

837

引用

页码：512A / 513A

页数：2

共 50 条

[1] THE ORALLY AVAILABLE SODIUM/TAUROCHOLATE CO-TRANSPORTING POLYPEPTIDE INHIBITOR A2342 BLOCKS HEPATITIS B AND D ENTRY IN VITRO
Bonn, Britta
Straengberg, Ellen
Uzelac, Ivana
Kirstgen, Michael
Goldmann, Nora
Glebe, Dieter
Geyer, Joachim
Lindstroem, Erik
GUT, 2022, 71 : A42 - A42
[2] The orally available sodium/taurocholate co-transporting polypeptide inhibitor A2342 blocks hepatitus B and D entry in vitro
Bonn, Britta
Straengberg, Ellen
Uzelac, Ivana
Kirstgen, Michael
Goldmann, Nora
Glebe, Dieter
Geyer, Joachim
Lindstroem, Erik
JOURNAL OF HEPATOLOGY, 2022, 77 : S843 - S843
[3] PRECLINICAL CHARACTERIZATION OF THE NOVEL, ORALLY BIOAVAILABLE NTCP INHIBITOR A7387
Strangberg, Ellen
Bonn, Britta
Phuong Phan
Uzelac, Ivana
Starke, Ingemar
Pal, Runa
Gaur, Ashwani
Kangarajan, Ramesh
Singh, Shivendra
Kulkarni, Santosh
Dawson, Paul A.
Lindstrom, Erik
HEPATOLOGY, 2023, 78 : S582 - S582
[4] Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway
Thress, Kenneth
MacIntyre, Terry
Wang, Haiyun
Whitston, Dave
Liu, Zhong-Ying
Hoffmann, Ethan
Wang, Tao
Brown, Jeffrey L.
Webster, Kevin
Omer, Charles
Zage, Peter E.
Zeng, Lizhi
Zweidler-McKay, Patrick A.
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (07) : 1818 - 1827
[5] Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway
Thress, K.
MacIntyre, T.
Wang, H.
Liu, Z. Y.
Hoffmann, E.
Wang, T.
Whitston, D.
Brown, J. L.
Webster, K.
Omer, C.
EJC SUPPLEMENTS, 2008, 6 (12): : 180 - 180
[6] Discovery of ITX 4520: A highly potent orally bioavailable hepatitis C virus entry inhibitor
Mittapalli, Gopi Kumar
Zhao, Fang
Jackson, Andrew
Gao, Hongfeng
Lee, Haekyung
Chow, Stephine
Kaur, Maninder Pal
Natalie Nguyen
Zamboni, Robert
McKelvy, Jeffrey
Wong-Staal, Flossie
Macdonald, James E.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (15) : 4955 - 4961
[7] PRECLINICAL CHARACTERIZATION OF PRO 206, AN ORALLY ACTIVE SMALL-MOLECULE HEPATITIS C (HCV) ENTRY INHIBITOR
Qian, D.
Coburn, G.
Han, A. Q.
de Muys, J. -M.
Gauss, C.
Provoncha, K.
Canfield, M.
Paul, D.
Mohamed, S.
Moorji, S.
Fisch, D.
Murga, J.
Rotshteyn, Y.
Maddon, P. J.
Olson, W. C.
JOURNAL OF HEPATOLOGY, 2009, 50 : S5 - S6
[8] Preclinical metabolism and disposition of an orally bioavailable macrocyclic FXIa inhibitor
Chacko, Silvi A.
Yang, Wu
Wang, Yufeng
Tian, Yuan
Hong, Yang
Wallace, Michael
Wang, Bonnie
Ewing, William R.
Luettgen, Joseph M.
Shu, Yue-Zhong
Christopher, Lisa J.
XENOBIOTICA, 2021, 51 (08) : 933 - 948
[9] Preclinical Characterization of TTI-281, a Novel, Orally Bioavailable BET Inhibitor: Predictive Biomarker Identification and Combination Treatment Analysis
Choi, Jaehyun
Wang, Chunlei
Wang, Zezhou
Schimmer, Aaron D.
Petrova, Penka S.
Slassi, Malik
Uger, Robert A.
BLOOD, 2016, 128 (22)
[10] Discovery of DS-8108b, a Novel Orally Bioavailable Renin Inhibitor
Nakamura, Yuji
Fujimoto, Teppei
Ogawa, Yasuyuki
Sugita, Chie
Miyazaki, Shojiro
Tamaki, Kazuhiko
Takahashi, Mizuki
Matsui, Yumi
Nagayama, Takahiro
Manabe, Kenichi
Mizuno, Makoto
Masubuchi, Noriko
Chiba, Katsuyoshi
Nishi, Takahide
ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (09): : 754 - 758

← 1 2 3 4 5 →